secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2024-02-27T23:59:59+00:00
Accession:  0001725160-24-000079
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis reports FY2023 cash $483M, azenosertib ORR 37%, appoints CMO/CBO
-------------------------------------------------------------------------

- Cash, equivalents and securities $482.9M at Dec 31, 2023; runway into 2026; plus $35M upfront from Immunome in Jan 2024.
- R&D expenses $189.6M (up 9.8%), G&A $64.4M (up 18%) versus FY2022.
- Azenosertib Phase 1 monotherapy showed 37% ORR and 6.5-month mPFS in platinum-resistant ovarian/USC cancer patients.
- Appointed Diana Hausman, M.D., as CMO and Kyle Rasbach, Ph.D., Pharm.D., as CBO.
- NDA submission for azenosertib in gynecologic malignancy targeted for 2026; multiple data readouts in 2024-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516024000079/0001725160-24-000079-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516024000079/zntl-20240227.htm
  HTML page:      https://secwatch.observer/filing/0001725160-24-000079

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer